Bausch Health Cos (NYSE:BHC) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Bausch Health Cos (NYSE:BHC) from a buy rating to a strong-buy rating in a report released on Saturday.

BHC has been the topic of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of Bausch Health Cos in a research report on Monday, December 29th. Barclays started coverage on Bausch Health Cos in a report on Monday, December 8th. They issued an “equal weight” rating and a $8.00 price target for the company. Truist Financial boosted their price objective on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Wednesday, January 7th. Finally, Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Five investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $8.67.

Bausch Health Cos Stock Performance

Shares of NYSE BHC opened at $5.89 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.30 and a debt-to-equity ratio of 57.48. The business’s 50 day moving average is $6.81 and its two-hundred day moving average is $6.71. The company has a market cap of $2.18 billion, a P/E ratio of 6.07 and a beta of 0.42. Bausch Health Cos has a 12 month low of $4.25 and a 12 month high of $8.69.

Institutional Investors Weigh In On Bausch Health Cos

A number of large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its position in Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock valued at $35,000 after purchasing an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares in the last quarter. Camelot Portfolios LLC bought a new stake in Bausch Health Cos during the 4th quarter worth about $59,000. Alpha Wealth Funds LLC bought a new stake in Bausch Health Cos during the 2nd quarter worth about $65,000. Finally, Stratos Wealth Advisors LLC bought a new position in shares of Bausch Health Cos in the second quarter worth about $67,000. 78.65% of the stock is currently owned by institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.